12:00 pm PDT – Registration and lunch
12:15 – 1:30 pm PDT – Roundtable discussion
McDermott Will & Emery LLP
275 Middlefield Road
Menlo Park, CA 94025
Pharmaceutical patents are vulnerable to attack in the inter partes review proceedings before the United States Patent and Trademark Office (USPTO). Join our interactive discussion on these new proceedings to learn how and why generic drug manufacturers are using the proceedings to enter the market more quickly and with less expense, relative to traditional Abbreviated New Drug Application (ANDA) district court challenges, by challenging the patent in a forum more favorable to the generic challenger. We will also examine options available to branded drug companies to protect their patents and to be prepared for inter partes review proceedings.
Among the questions to be addressed are:
Why is inter partes review an effective strategy either in parallel with or as an alternative to traditional ANDA litigation?
What are the important and practical tips for inter partes review proceedings, including:
- Effective challenges
- Insights on the proceeding
- Limiting cost/disruption to your day-to-day business
What are effective strategies for the patent owner?
Does the existence of the inter partes review proceeding change how pharmaceutical companies should apply for and prosecute their patents?
This program will feature speakers with industry, government and outside counsel experience and perspectives. Bernie Knight, the USPTO General Counsel from 2010 to 2013, who led the legal development and review of the regulations implementing the new inter partes review and has advised pharmaceutical companies on effective strategies using the new proceedings; Judy Mohr, who represents pharmaceutical companies before the USPTO in inter partes reviews and prosecution matters; Paul Simboli, Vice President, Intellectual Property and Assistant General Counsel of Depomed, Inc.; and Judith Hom, who has more than a decade of experience in intellectual property litigation, will lead the discussion.
Bernard J. Knight, Partner, McDermott Will & Emery
Judy Mohr, Partner, McDermott Will & Emery
Paul Simboli, Chief IP Counsel, Depomed
Judith S.H. Hom, Of Counsel, McDermott Will & Emery
For more information, please contact Nick Latham.
CLE credit is pending in California, Illinois, New York and Texas. A Uniform Certificate of Attendance will be made available to participants requesting CLE credit in all other states.
McDermott Will & Emery's Intellectual Property Roundtables are designed for the educational benefit of a company president, CEO, general counsel or other executive with an interest in intellectual property. Please be advised McDermott has the right to restrict attendance and may limit participation in this event.